Scholarlink

<p>Human papillomavirus (HPV) vaccine coverage (VC) remains suboptimal in many countries. The PrevHPV national research programme aimed to codevelop and evaluate a three-component intervention including: ‘education and motivation’ of adolescents, ‘at-school vaccination’, ‘general practitioners (GPs)’ training’. We assessed its impact on VC at one year through a cluster randomized trial (July 2021–April 2022) conducted in French municipalities (clusters) receiving 0, 1, 2, or 3 components. The outcomes (≥ 1-dose and full HPV VC at one year among 11–14-year-olds) were estimated using data from the national health reimbursement database and data collected during the trial. We performed intention-to-treat and post-hoc analysis adjusted for the dose of intervention using cluster-level linear models. Ninety-one municipalities were included. ‘At-school vaccination’ significantly increased ≥ 1-dose VC, in both intention-to-treat (+ 2.85 percentage points (pp), 95%CI = 0.62 to 5.09) and post-hoc analysis (+ 4.60&#xa0;pp, 95%CI = 1.79 to 7.41). No significant effects were found for the other components. Results were similar for full VC. ‘At-school vaccination’ significantly increased VC only in municipalities with the lowest access to GPs. School-based vaccination was effective in increasing HPV VC in the medium term and may reduce VC healthcare access-driven territorial disparities. Challenges remain in parental engagement and consent for vaccination at school.</p><p><i>Trial registration</i>: Clinicaltrials.gov, NCT04945655. Registered 30 June 2021.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

One-year impact on HPV vaccination coverage of a school- and primary care-based intervention: the PrevHPV cluster randomised trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月22日

查看全文
  • Aurélie Bocquier,
  • Morgane Michel,
  • Judith E. Mueller,
  • Maïa Simon,
  • Amandine Gagneux-Brunon,
  • Aurélie Gauchet,
  • Serge Gilberg,
  • Anne-Sophie Le Duc-Banaszuk,
  • Sébastien Bruel,
  • Bruno Giraudeau,
  • Nathalie Thilly,
  • Stéphanie Bonnay,
  • Estelle Fall,
  • Marie Ecollan,
  • Josselin Le Bel,
  • Henri Partouche,
  • Juliette Pinot,
  • Louise Rossignol,
  • Arthur Tron,
  • Dragos-Paul Hagiu,
  • Catherine Juneau,
  • Julien Ailloud,
  • Marion Branchereau,
  • Florian Jeanleboeuf,
  • Géraldine Jambon,
  • Elisabeth Botelho-Nevers,
  • Emilie Darlington,
  • Mabrouk Nekaa,
  • Karine Chevreul,
  • Jocelyn Raude,
  • Jonathan Sicsic,
  • Anne-Sophie Barret,
  • Sandra Chyderiotis,
  • Damien Oudin-Doglioni,
  • Josee Dussault,
  • Clémence Castagnet,
  • Mélanie Simony

摘要

Human papillomavirus (HPV) vaccine coverage (VC) remains suboptimal in many countries. The PrevHPV national research programme aimed to codevelop and evaluate a three-component intervention including: ‘education and motivation’ of adolescents, ‘at-school vaccination’, ‘general practitioners (GPs)’ training’. We assessed its impact on VC at one year through a cluster randomized trial (July 2021–April 2022) conducted in French municipalities (clusters) receiving 0, 1, 2, or 3 components. The outcomes (≥ 1-dose and full HPV VC at one year among 11–14-year-olds) were estimated using data from the national health reimbursement database and data collected during the trial. We performed intention-to-treat and post-hoc analysis adjusted for the dose of intervention using cluster-level linear models. Ninety-one municipalities were included. ‘At-school vaccination’ significantly increased ≥ 1-dose VC, in both intention-to-treat (+ 2.85 percentage points (pp), 95%CI = 0.62 to 5.09) and post-hoc analysis (+ 4.60 pp, 95%CI = 1.79 to 7.41). No significant effects were found for the other components. Results were similar for full VC. ‘At-school vaccination’ significantly increased VC only in municipalities with the lowest access to GPs. School-based vaccination was effective in increasing HPV VC in the medium term and may reduce VC healthcare access-driven territorial disparities. Challenges remain in parental engagement and consent for vaccination at school.

Trial registration: Clinicaltrials.gov, NCT04945655. Registered 30 June 2021.